PLAU and cancer: The 5-azacytidine is an epigenetic drug that inhibits DNA methylation, specifically urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP2) promoter methylation, thus causing cancer growth inhibition and induction of cancer invasiveness, respectively.